Why the study?
Does molecular genetic testing improve the diagnosis of Carney complex compared to clinical and pathologic findings alone in at-risk individuals?
Does molecular genetic testing improve the diagnosis of Carney complex compared to clinical and pathologic findings alone in at-risk individuals?
Molecular genetic analysis provides an important diagnostic method for Carney complex, overcoming difficulties in establishing a diagnosis based solely on clinical and pathologic findings.
Answers are grounded in this paper and cite their sources.
Case-level data suggest haplotype analysis aids Carney complex diagnosis; leaves open prospective validation before wider adoption.
We describe an individual in whom molecular genetic testing provided a diagnosis of the Carney complex, an autosomal dominant syndrome comprising cutaneous and cardiac myxomas, spotty pigmentation of the skin, and endocrinopathy. Recently, we localized the Carney complex disease gene to chromosome region 17q2. Our patient was a member of a family segregating the Carney complex, but was not, himself, initially thought to be affected. Haplotype analysis based on genotyping studies with 17q2 microsatellites predicted that this individual was, in fact, affected by Carney complex and was at risk for development of myxomas. Further clinical evaluation and re-review of prior pathologic studies, then, confirmed the DNA-based diagnosis. This report highlights the difficulty in establishing a diagnosis of Carney complex based on clinical and pathologic findings alone, and we suggest that molecular genetic analyses provide an important diagnostic method for this familial myxoma syndrome.
No takes yet. Share an insight, caveat, or question.
Goldstein et al. (1999) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: